Ignite Creation Date:
2025-12-24 @ 4:48 PM
Ignite Modification Date:
2025-12-24 @ 4:48 PM
Study NCT ID:
NCT06781450
Status:
RECRUITING
Last Update Posted:
2025-01-30
First Post:
2024-12-03
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context
Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04-23
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12
Completion Date Type:
ESTIMATED
First Submit Date:
2024-12-03
First Submit QC Date:
None
Study First Post Date:
2025-01-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-01-28
Last Update Post Date:
2025-01-30
Last Update Post Date Type:
ACTUAL